Standout Papers

EAU Guidelines on Renal Cell Carcinoma: 2014 Update 2015 2026 2018 2022 2.1k
  1. EAU Guidelines on Renal Cell Carcinoma: 2014 Update (2015)
    Börje Ljungberg, Karim Bensalah et al. European Urology
  2. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update (2019)
    Börje Ljungberg, Laurence Albigès et al. European Urology
  3. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update (2022)
    Börje Ljungberg, Laurence Albigès et al. European Urology
  4. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (2020)
    Thomas Powles, Elizabeth R. Plimack et al. The Lancet Oncology
  5. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial (2020)
    Laurence Albigès, Nizar M. Tannir et al. ESMO Open
  6. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib (2018)
    Axel Bex, Peter F.A. Mulders et al. JAMA Oncology
  7. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (2022)
    Robert J. Motzer, Thomas Powles et al. The Lancet Oncology
  8. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma (2023)
    Toni K. Choueiri, Thomas Powles et al. New England Journal of Medicine

Immediate Impact

4 by Nobel laureates 27 from Science/Nature 76 standout
Sub-graph 1 of 22

Citing Papers

A vision–language foundation model for precision oncology
2025 StandoutNature
Tumour vasculature at single-cell resolution
2024 StandoutNature
2 intermediate papers

Works of Thomas Powles being referenced

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
2020 Standout
A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
2017

Author Peers

Author Last Decade Papers Cites
Thomas Powles 9634 6177 3957 233 11.5k
Laurence Albigès 10230 6270 4944 448 13.7k
Sergio Bracarda 7422 5689 4285 230 11.3k
Axel Bex 10516 7235 3441 335 14.2k
Frédéric Rolland 6597 4685 4228 141 11.3k
Christine Chevreau 9987 6252 6054 308 15.3k
Daniel Y.C. Heng 7356 4858 3315 134 9.1k
Viktor Grünwald 6560 5407 3976 320 10.1k
Gary R. Hudes 6724 6084 3485 101 10.5k
I. Bodrogi 6343 4241 3498 77 10.2k
Brian Schwartz 5784 7652 5154 143 14.2k

All Works

Loading papers...

Rankless by CCL
2026